PresentationGood day, ladies and gentlemen, and welcome to today's GRAIL analyst call. [Operator Instructions] Please be advised that this conference call is being recorded.Unknown Executive Thanks, operator, and thanks, everyone, for joining us today to discuss detailed PATHFINDER 2 study results presented over the weekend at ESMO. On this morning's call are Bob Ragusa, our Chief Executive Officer; Aaron Freidin, our Chief Financial Officer; Josh Ofman, President; Sir Harpal Kumar, President, Internationa ...

Core Insights - GRAIL, Inc. has announced a partnership with athenahealth to integrate its Galleri multi-cancer early detection test into athenahealth's EHR solution, athenaOne, enhancing the ordering process for clinicians [1][2][3] Company Overview - GRAIL is focused on early cancer detection using advanced technologies such as next-generation sequencing and machine learning, aiming to alleviate the global burden of cancer [4] - The Galleri test identifies DNA shed by cancer cells through a simple blood draw, allowing for the detection of multiple deadly cancers before symptoms appear [6] Partnership Details - The integration with athenaCoordinator Core will enable over 160,000 U.S. clinicians to order the Galleri test directly within their EHR, streamlining the process and reducing administrative burdens [2][3] - The Galleri test results will be automatically available in the patient chart, further simplifying the workflow for healthcare providers [2] Test Specifications - The Galleri test is recommended for adults aged 50 or older with an elevated risk for cancer and should be used alongside standard cancer screenings [6][9] - The test can indicate the origin of cancer, providing healthcare providers with valuable information for further investigation [6] Sensitivity Data - The sensitivity of the Galleri test varies by cancer type, with pancreas cancer showing 83.7% sensitivity overall, and liver/bile duct cancer at 93.5% [8]